US biotech to submit new psoriasis treatment to the FDA in summer

Dermavant Sciences has presented an interim analysis of phase III results from trial involving new treatment for plaque psoriasis, which will form basis for FDA new drug application.

In 2022, US skin doctors may get their hands on a new tool for treating patients with plaque psoriasis.

So hopes biotech company Dermavant Sciences, which, mid-year, will be submitting a new drug application to the US Food and Drug Administration (FDA) on the basis of the drug tapinarof's new phase III trial results.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs